Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
12
01
2023
revised:
15
02
2023
accepted:
15
03
2023
medline:
2
8
2023
pubmed:
17
4
2023
entrez:
16
4
2023
Statut:
ppublish
Résumé
Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers have obtained FDA tissue-agnostic approval for targeted therapies and immunotherapies. Those include BRAFV600E mutations, RET fusions, NTRK fusions, high tumor mutation burden (TMB), and deficient mismatch repair/high microsatellite instability (dMMR/MSI-High). Herein, we have used data from AACR project GENIE to explore the clinico-genomic landscape of these alterations. AACR GENIE is a publicly accessible registry of genomic data from multiple collaborating cancer centers. Current database (version 13.0) includes sequencing data of 168,423 samples collected from patients with different cancers. We were able to identify BRAFV600E, RET fusions, NTRK fusions, and high TMB in 2.9%, 1.6%, 1.5%, and 15.2% of pan-cancer samples, respectively. In this article, we describe the distribution of those tissue-agnostic targets among different cancer types. In addition, we summarize the current prospect on the biology of these alterations and evidence on approved drugs, including pembrolizumab, dostarilmab, larotrectinib, entrectinib, selpercatinib, and dabrafenib/trametinib combination.
Identifiants
pubmed: 37061987
pii: 725160
doi: 10.1158/1078-0432.CCR-23-0090
pmc: PMC10390861
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2753-2760Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA180964
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA273168
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA242845
Pays : United States
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Ann Oncol. 2017 Mar 1;28(3):634-641
pubmed: 27993793
J Thorac Oncol. 2022 Jan;17(1):103-115
pubmed: 34455067
Nature. 1994 Jan 27;367(6461):375-6
pubmed: 7906866
Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67
pubmed: 15982921
JAMA Oncol. 2021 Feb 1;7(2):316
pubmed: 33331847
J Clin Oncol. 2019 Jun 10;37(17):1460-1469
pubmed: 30892987
JCO Precis Oncol. 2021 Nov 3;5:
pubmed: 34778692
Am J Clin Pathol. 1980 Jan;73(1):3-11
pubmed: 6986079
Ann Oncol. 2022 Apr;33(4):406-415
pubmed: 35026411
N Engl J Med. 2012 Feb 23;366(8):707-14
pubmed: 22356324
ESMO Open. 2023 Apr;8(2):100788
pubmed: 36842301
Nat Rev Drug Discov. 2022 Aug;21(8):548
pubmed: 35794466
Oncologist. 2013;18(7):865-75
pubmed: 23814043
Oncogene. 1989 Dec;4(12):1519-21
pubmed: 2687772
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Endocr Rev. 2001 Apr;22(2):153-83
pubmed: 11294822
J Clin Oncol. 2021 Feb 1;39(4):273-284
pubmed: 33503393
Sci Rep. 2022 Nov 28;12(1):20495
pubmed: 36443366
Cancer Treat Rev. 2019 Dec;81:101911
pubmed: 31715421
Ann Oncol. 2020 Sep;31(9):1115-1118
pubmed: 32771306
J Cell Physiol. 2003 May;195(2):168-86
pubmed: 12652644
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nat Genet. 1998 Feb;18(2):184-7
pubmed: 9462753
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Nat Rev Clin Oncol. 2020 Sep;17(9):555-568
pubmed: 32528101
Nature. 1993 Jun 3;363(6428):458-60
pubmed: 8099202
Semin Oncol. 2006 Aug;33(4):407-20
pubmed: 16890796
Nat Med. 2022 Aug;28(8):1640-1645
pubmed: 35962206
Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85
pubmed: 15520807
Trends Cancer. 2023 Mar;9(3):237-249
pubmed: 36494311
Front Immunol. 2017 Aug 02;8:829
pubmed: 28824608
Ann Oncol. 2017 Jul 01;28(7):1631-1639
pubmed: 28475671
Trends Cancer. 2022 Feb;8(2):135-144
pubmed: 34887213
Lancet Oncol. 2018 Oct;19(10):1315-1327
pubmed: 30219628
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Lancet Oncol. 2022 Jan;23(1):53-64
pubmed: 34838156
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Cell. 1985 Sep;42(2):581-8
pubmed: 2992805
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
Hum Mol Genet. 1993 Jul;2(7):851-6
pubmed: 8103403
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Acta Oncol. 2009;48(6):915-20
pubmed: 19363713
ESMO Open. 2016 Mar 18;1(2):e000023
pubmed: 27843590
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
JAMA Oncol. 2018 Mar 01;4(3):384-388
pubmed: 29188284
Clin Cancer Res. 2010 Dec 15;16(24):5936-41
pubmed: 20930041
J Clin Oncol. 2020 Nov 20;38(33):3895-3904
pubmed: 32758030
Cancer Discov. 2019 Mar;9(3):329-341
pubmed: 30770389
J Clin Oncol. 2022 Dec 20;40(36):4178-4188
pubmed: 35862871
Oncogene. 2000 Nov 20;19(49):5590-7
pubmed: 11114739
Nat Rev Clin Oncol. 2018 Mar;15(3):151-167
pubmed: 29134959
Oncogene. 2018 Jun;37(24):3183-3199
pubmed: 29540830
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Cancer Cell Int. 2019 Aug 7;19:209
pubmed: 31406485
Br J Cancer. 2010 Jun 8;102(12):1724-30
pubmed: 20531415
Eur J Cancer. 2019 Mar;109:61-69
pubmed: 30690294
Lancet Oncol. 2022 Oct;23(10):1261-1273
pubmed: 36108661
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
Clin Cancer Res. 2021 Oct 1;27(19):5225-5235
pubmed: 34158360
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Lancet Oncol. 2012 Nov;13(11):1087-95
pubmed: 23051966
Lancet Oncol. 2016 May;17(5):642-50
pubmed: 27080216
Ann Oncol. 2017 Oct 01;28(10):2581-2587
pubmed: 28961848
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
N Engl J Med. 2012 Jan 19;366(3):207-15
pubmed: 22256804
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Ann Oncol. 2018 Aug 1;29(8):1869-1876
pubmed: 29912274
N Engl J Med. 2020 Aug 27;383(9):825-835
pubmed: 32846061
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
Mol Cancer. 2014 Jul 21;13:176
pubmed: 25047660
J Clin Oncol. 2023 Jan 20;41(3):664-674
pubmed: 36375115
Nat Rev Cancer. 2023 Jan;23(1):43-54
pubmed: 36434139